Federico Mingozzi

    Federico Mingozzi photo
    Federico Mingozzi Ph.D.
    Chief Scientific Officer

    Dr. Federico Mingozzi is the chief scientific officer at Spark Therapeutics, bringing two decades of experience in gene therapy, immunology, as well as biochemistry and molecular biology in both industry and academic settings.

    Federico began his scientific career studying the genetic bases of bleeding disorders. At the Children’s Hospital Philadelphia (CHOP) he conducted pioneering studies on liver gene transfer with adeno-associated virus (AAV) vectors and immunology. Federico was involved in several first-in-human clinical studies of gene therapy based on the AAV vector platform while serving as the director of translational research the Center for Cellular and Molecular Therapeutics, at CHOP. He also led studies aimed at the characterization of human immune responses to AAV vectors and the development of strategies to modulate vector immunogenicity.

    He then joined the French National Institute of Health and Medical Research (INSERM) as Research Director and Genethon, a leading French nonprofit R&D organization focused on gene therapy for rare diseases, as Team Leader. There, he spearheaded the development of in vivo gene therapies for inherited diseases. His work continued to focus on the characterization of human immune responses to AAV vectors and on the development of strategies to overcome immune responses in gene transfer.

    Federico currently serves as faculty at the Pierre and Marie Curie University in Paris, France, and Universitat Autonoma de Barcelona, Spain. He received his bachelor’s degree in biology and his Ph.D. in biochemistry and molecular biology from the University of Ferrara in Italy, and his M.B.A. from Drexel University. Throughout his distinguished career, Federico has received several awards and has contributed to more than 90 publications, including seminal findings in the field of AAV gene therapy.

    Lisa Dalton

      Lisa Dalton photo
      Lisa Dalton
      Chief People Officer
      Lisa Dalton has more than 20 years of strategic and operational human resources experience across the biopharmaceutical and financial services industries. She began her tenure at Spark Therapeutics as the Head of Human Resources and after joining the company’s corporate management team, was made Chief Human Resource Officer. In January 2019, Lisa was appointed Chief People Officer and oversees human resources, information technology and corporate facilities. As a core member of Spark’s management team, she has been instrumental in shaping the culture, capabilities, operating model and employee experience during a period of tremendous growth and evolution from a pre-IPO start-up to a fully integrated, commercial gene therapy company.

      Lisa was previously vice president, human resources at Shire, where she led various human resources functions to meet the needs of a high-growth organization, including human resources-related merger and acquisition efforts, the total rewards function and the human resources operations function. While on international assignment in Switzerland, Lisa played a critical role in planning and launching Shire’s European hub, where she was a member of the site leadership team, championed the culture and values of the organization and had oversight of the talent strategies for the newly established site.

      Lisa also has held roles in human resources with Franklin Templeton Investments, Applied Biosystems and Goldman Sachs.

      Lisa holds an M.B.A. from Rutgers University School of Business and a B.A. in psychology from Pennsylvania State University.